TissueGen's ELUTE Fiber Wins 2015 R&D 100 Award

DALLAS, TX--(Marketwired - Dec 1, 2015) - TissueGen^® Inc., developer of ELUTE^® fiber, groundbreaking biodegradable fiber for delivery of the broadest range of therapeutic drugs, has been honored with a prestigious R&D 100 Gold Award in the Market Disruptor Services Special Recognition category. ELUTE fiber enables advanced drug delivery, nerve regeneration, and tissue engineering applications never before possible.

Widely recognized as the "Oscars of Invention," the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics. The R&D 100 Awards span industry, academia, and government-sponsored research.

TissueGen's ELUTE fiber directly replaces standard fibers in biodegradable monofilament formats and medical textiles and may significantly improve clinical outcomes by delivering therapeutic agents directly at the surgical site. Through controlled release of drugs at the site of implantation, ELUTE fiber enables medical devices to orchestrate the body's healing and regenerative responses. 

"We are honored to receive the R&D 100 Award for Market Disruptor Services, affirmation that TissueGen's drug delivery technology enables truly groundbreaking products," said Christopher Knowles, CEO, TissueGen. "ELUTE fiber is revolutionizing how medical applications are approached and we anticipate wider adoption of ELUTE fiber in the year ahead by the pharmaceutical, therapeutic, and medical device industries." 

TissueGen's patented manufacturing process occurs at room temperature, thereby protecting the biological activity of the widest range of pharmaceutical and therapeutic agents including live biologics for controlled delivery from ELUTE fiber.

About TissueGen

TissueGen^® Inc. is the developer of ELUTE^® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen has more than four decades of cumulative experience in extruding biodegradable polymer fibers with broad drug delivery capabilities. ELUTE fiber can directly replace standard fibers used in biodegradable textiles currently on the market and provide significantly improved clinical outcomes by delivering therapeutic agents directly at the site of the implant. By delivering drugs and growth factors at the site of implantation, ELUTE fiber enables medical devices to guide the body's healing and regenerative processes. For more information, please visit www.tissuegen.com.